

Jette Lautrup Frederiksen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7976473/publications.pdf>

Version: 2024-02-01

48
papers

2,386
citations

361045

20
h-index

233125

45
g-index

48
all docs

48
docs citations

48
times ranked

2845
citing authors

#	ARTICLE	IF	CITATIONS
1	Assessment of Artificial Intelligence Automatic Multiple Sclerosis Lesion Delineation Tool for Clinical Use. <i>Clinical Neuroradiology</i> , 2022, 32, 643-653.	1.0	5
2	Reactivity of Rheumatoid Arthritis-Associated Citrulline-Dependent Antibodies to Epstein-Barr Virus Nuclear Antigen1-3. <i>Antibodies</i> , 2022, 11, 20.	1.2	5
3	Leveraging Visual Outcome Measures to Advance Therapy Development in Neuroimmunologic Disorders. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2022, 9, .	3.1	32
4	Blood-brain barrier permeability changes in the first year after alemtuzumab treatment predict 2-year outcomes in relapsing-remitting multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 63, 103891.	0.9	6
5	MIF in the cerebrospinal fluid is decreased during relapsing-remitting while increased in secondary progressive multiple sclerosis. <i>Journal of the Neurological Sciences</i> , 2022, 439, 120320.	0.3	5
6	Multifocal visual evoked potential evaluation for diagnosis of acute optic neuritis and for prediction of visual outcome and ganglion cell layer thinning following optic neuritis. <i>Multiple Sclerosis Journal</i> , 2021, 27, 1717-1726.	1.4	1
7	Predictive value of optical coherence tomography, multifocal visual evoked potentials, and full-field visual evoked potentials of the fellow, non-symptomatic eye for subsequent multiple sclerosis development in patients with acute optic neuritis. <i>Multiple Sclerosis Journal</i> , 2021, 27, 391-400.	1.4	14
8	Neurovascular contact plays no role in trigeminal neuralgia secondary to multiple sclerosis. <i>Cephalalgia</i> , 2021, 41, 593-603.	1.8	13
9	Development and evaluation of a manual segmentation protocol for deep grey matter in multiple sclerosis: Towards accelerated semi-automated references. <i>NeuroImage: Clinical</i> , 2021, 30, 102659.	1.4	3
10	The levels of the serine protease HTRA1 in cerebrospinal fluid correlate with progression and disability in multiple sclerosis. <i>Journal of Neurology</i> , 2021, 268, 3316-3324.	1.8	6
11	APOSTEL 2.0 Recommendations for Reporting Quantitative Optical Coherence Tomography Studies. <i>Neurology</i> , 2021, 97, 68-79.	1.5	96
12	Anti-myelin oligodendrocyte glycoprotein antibodies in a girl with good recovery after five episodes of prior idiopathic optic neuritis. <i>American Journal of Ophthalmology Case Reports</i> , 2021, 22, 101060.	0.4	0
13	Specificity of Anti-Citrullinated Protein Antibodies to Citrullinated Î±-Enolase Peptides as a Function of Epitope Structure and Composition. <i>Antibodies</i> , 2021, 10, 27.	1.2	4
14	The effectiveness of natalizumab vs fingolimodâ€”A comparison of international registry studies. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 53, 103012.	0.9	8
15	2021 MAGNIMSâ€”CMSCâ€”NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis. <i>Lancet Neurology</i> , The, 2021, 20, 653-670.	4.9	302
16	Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: A Subgroup Analysis From Three International Cohorts. <i>CNS Drugs</i> , 2021, 35, 1217-1232.	2.7	8
17	Functionalâ€”structural assessment of the optic pathways in patients with optic neuritis. <i>Documenta Ophthalmologica</i> , 2020, 140, 159-168.	1.0	3
18	Sensitive Assessment of Acute Optic Neuritis by a New, Digital Flicker Test. <i>Ophthalmic Research</i> , 2020, 63, 332-340.	1.0	1

#	ARTICLE	IF	CITATIONS
19	New Algorithms Improving PML Risk Stratification in MS Patients Treated With Natalizumab. <i>Frontiers in Neurology</i> , 2020, 11, 579438.	1.1	9
20	Current Evidence on the Efficacy of Gluten-Free Diets in Multiple Sclerosis, Psoriasis, Type 1 Diabetes and Autoimmune Thyroid Diseases. <i>Nutrients</i> , 2020, 12, 2316.	1.7	37
21	Fibrinogen: A potential biomarker for predicting disease severity in multiple sclerosis.. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 46, 102509.	0.9	8
22	Aggressive multiple sclerosis (2): Treatment. <i>Multiple Sclerosis Journal</i> , 2020, 26, 1045-1063.	1.4	21
23	Aggressive multiple sclerosis (1): Towards a definition of the phenotype. <i>Multiple Sclerosis Journal</i> , 2020, 26, 1031-1044.	1.4	39
24	Reader response: Epidemiology of NMOSD in Sweden from 1987 to 2013: A nationwide population-based study. <i>Neurology</i> , 2020, 94, 1048-1049.	1.5	0
25	Intrathecal IgM as a Prognostic Marker in Multiple Sclerosis. <i>Molecular Diagnosis and Therapy</i> , 2020, 24, 263-277.	1.6	11
26	MAGNIMS consensus recommendations on the use of brain and spinal cord atrophy measures in clinical practice. <i>Nature Reviews Neurology</i> , 2020, 16, 171-182.	4.9	150
27	Epstein-Barr Virus and Multiple Sclerosis. <i>Frontiers in Immunology</i> , 2020, 11, 587078.	2.2	52
28	A free and simple computerized screening test for visual field defects. <i>Scandinavian Journal of Psychology</i> , 2019, 60, 289-294.	0.8	5
29	Comparative effectiveness of teriflunomide and dimethyl fumarate. <i>Neurology</i> , 2019, 92, e1811-e1820.	1.5	36
30	Author response: Nationwide prevalence and incidence study of neuromyelitis optica spectrum disorder in Denmark. <i>Neurology</i> , 2019, 93, 723-723.	1.5	0
31	The role of gluten in multiple sclerosis: A systematic review. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 27, 156-163.	0.9	21
32	Optical coherence tomography in multiple sclerosis. <i>Eye</i> , 2018, 32, 884-888.	1.1	93
33	Link between overweight/obese in children and youngsters and occurrence of multiple sclerosis. <i>Journal of Neurology</i> , 2018, 265, 2755-2763.	1.8	7
34	Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension. <i>Lancet Neurology</i> , The, 2018, 17, 405-415.	4.9	238
35	Adherence to subcutaneous interferon beta-1a treatment using an electronic injection device: a prospective open-label Scandinavian noninterventional study (the ScanSmart study). <i>Patient Preference and Adherence</i> , 2018, Volume 12, 569-575.	0.8	9
36	Nationwide prevalence and incidence study of neuromyelitis optica spectrum disorder in Denmark. <i>Neurology</i> , 2018, 91, e2265-e2275.	1.5	84

#	ARTICLE	IF	CITATIONS
37	Assessment of Opicinumab in Acute Optic Neuritis Using Multifocal Visual Evoked Potential. CNS Drugs, 2018, 32, 1159-1171.	2.7	38
38	Safety and efficacy of opicinumab in acute optic neuritis (RENEW): a randomised, placebo-controlled, phase 2 trial. Lancet Neurology, The, 2017, 16, 189-199.	4.9	210
39	Multifocal visual evoked potentials in optic neuritis and multiple sclerosis: A review. Clinical Neurophysiology, 2017, 128, 1234-1245.	0.7	35
40	Retinal ganglion cell analysis in multiple sclerosis and optic neuritis: a systematic review and meta-analysis. Journal of Neurology, 2017, 264, 1837-1853.	1.8	91
41	Retinal layer segmentation in multiple sclerosis: a systematic review and meta-analysis. Lancet Neurology, The, 2017, 16, 797-812.	4.9	397
42	The association between multiple sclerosis and uveitis. Survey of Ophthalmology, 2017, 62, 89-95.	1.7	35
43	Vaccines and multiple sclerosis: a systematic review. Journal of Neurology, 2017, 264, 1035-1050.	1.8	117
44	Rhabdomyolysis following interferon-beta treatment in a patient with multiple sclerosis – A case report. Multiple Sclerosis and Related Disorders, 2016, 8, 93-95.	0.9	4
45	Zinc in Multiple Sclerosis. ASN Neuro, 2016, 8, 175909141665151.	1.5	56
46	DETECTION OF ANTIBODIES TO THE 20S PROTEASOME BY ELISA. Journal of Immunoassay and Immunochemistry, 2013, 34, 384-392.	0.5	1
47	Serial Visual Evoked Potentials in 90 Untreated Patients With Acute Optic Neuritis. Survey of Ophthalmology, 1999, 44, S54-S62.	1.7	67
48	PCR typing of DNA fragments of the two short tandem repeat (STR) systems upstream of the human myelin basic protein (MBP) gene in Danes and Greenland Eskimos. Forensic Science International, 1996, 78, 139-156.	1.3	3